Hypoxic cell cytotoxin tirapazamine induces acute changes in tumor energy metabolism and pH: A 31P magnetic resonance spectroscopy study

Radiation Oncology Investigations

Volumn 6, Issue 6, 1998, Pages 249-254

  Aboagye, Eric O ^a   Dillehay, Larry E ^a,b   Bhujwalla, Zaver M ^a   Lee, Ding Jen ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Magnetic resonance spectroscopy; pH; Tirapazamine; Tumor energy metabolism

Indexed keywords

FLUNARIZINE; HYDRALAZINE; NICOTINAMIDE; PLATINUM DERIVATIVE; TIRAPAZAMINE;

ANESTHESIA; ANIMAL MODEL; ARTICLE; BIOENERGY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENERGY METABOLISM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ENERGY METABOLISM; HYDROGEN-ION CONCENTRATION; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NUCLEOTIDES; PHOSPHATES; TRIAZINES;

EID: 0032432843     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1998)6:6<249::AID-ROI1>3.0.CO;2-C     Document Type: Article

References (26)

1. Brown JM, Lemmon MJ. Potentiation by hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990;50: 7745-7749.
2. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993;53:4633-4636.
3. Lartigau E, Guichard M. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumors. Br J Cancer 1996;73:1480-1485.
4. Zeman EM, Hirst VK, Lemmon MJ, Brown JM. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233. Radiother Oncol 1988; 12:209-218.
5. Fitzsimmons SA, Lewis AD, Riley RJ, Workman P. Reduction of 3-amino-1,2,4,-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis 1994;15: 1503-1510.
6. Lloyd RV, Duling DR, Rumyantseva GV, Mason RP, Bridson PK. Microsomal reduction of 3-amino-1,2,4-benzotriazine-1,4-dioxide to a free radical. Mol Pharmacol 1991;40:440-455.
7. Doherty N, Hancock SL, Kaye S, Coleman CN, Shulman L, Marquez C, Mariscal C, Rampling R, Senan S, Roemeling RV. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int J Radiat Oncol Biol Phys 1994;29:379-382.
8. Graham MA, Senan S, Robin H Jr, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, Workman P. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol 1997;40:1-10.
9. Johnson CA, Kilpatrick D, von Roemeling R, Langer C, Graham MA, Greenslade D, Kennedy G, Keenan E, O'Dwyer PJ. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J Clin Oncol 1997;15:773-780.
10. Bedikian AY, Legha SS, Eton O, Buziad AC, Papadopoulos N, Coates S, Simmons T, Neefe J, von Roemeling R. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann Oncol 1997;8:363-367.
11. Elwell JH, Siim BG, Evans JW, Brown JM. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Biochem Pharmacol 1997;54:249-257.
12. Kim IH, Brown JM. Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int J Radiat Oncol Biol Phys 1994;29:493-497.
13. Ara G, Colman CN, Teicher BA. SR-4233 (tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cells. Cancer Lett 1994;85:195-203.
14. Moon RB, Richards JH. Determination of intracellular pH by 31P magnetic resonance. J Biol Chem 1973;248: 7276-7278.
15. Bhujwalla ZM, Tozer GM, Field SB, Maxwell RJ, Griffiths JR. The energy metabolism of RIF-1 tumors following hydralazine. Radiother Oncol 1990;19:281-291.
16. Dunn JF, Frostick S, Adams GE, Stratford IJ, Howells N, Hogan G, Radda GK. Induction of tumor hypoxia by a vasoactive agent. A combined NMR and radiobiological study. FEBS Lett 1989;249:343-347.
17. Okunieff P, Kallinowski F, Vaupel P, Neuringer L. Effects of hydralazine-induced vasodilation on the energy metabolism of murine tumors studied by in vivo 31P nuclear magnetic resonance spectroscopy. JNCI 1988; 80:745-750.
18. Bhujwalla ZM, Shungu DC, Glickson JD. Effects of blood flow modifiers on tumor metabolism observed in vivo by proton magnetic resonance spectroscopic imaging. Magn Reson Med 1996;36:204-211.
19. Nordsmark M, Grau C, Horsman MR, Jorgensen HS, Overgaard J. Relationship between tumor oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model. Acta Oncol 1995;34:329-334.
20. Wood PJ, Counsell CJR, Bremner JCM, Horsman MR, Adams GE. The measurement of radiosensitizer-induced changes in mouse tumor metabolism by 31P magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys 1991;20:291-294.
21. Durand RE, Olive PL. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Invest 1997;5:213-219.
22. Aboagye EO, Dillehay LE, Bhujwalla ZM, Lee D-J. Effect of tirapazamine on the energy metabolism of RIF-1 tumors. In: Tenth International Conference on Chemical Modifiers of Cancer Treatment, Clearwater, Florida. 1998. p 77.
23. Wouters BG, Delahoussaye YM, Dorie MJ, Peters KL, Brown JM. Loss of mitochondrial membrane potential after aerobic exposure to tirapazamine. In: Tenth International Conference on Chemical Modifiers of Cancer Treatment, Clearwater, Florida. 1998. p 73.
24. Atema A, Buurman KJH, Noteboom E, Smets LA. Potentiation of DNA-adduct formation and cytotoxicity of platinum-containing drugs by low pH. Int J Cancer 1993;54:166-172.
25. Jahde E, Glusenkamp KH, Kunder I, Hulser DF, Tietze LF, Rajewsky MF. Hydrogen-ion-mediated enhancement of cytotoxicity of bis-chloroethylating drugs in rat mammary carcinoma cells in vitro. Cancer Res 1989; 49:2965-2972.
26. Laurencot CM, Kennedy KA. Influence of pH on the cytotoxicity of cisplatin in EMT6 mouse mammary tumor cells. Oncol Res 1995;7:371-379.